The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease

被引:26
作者
Van Dalen, A
Barak, V
Cremaschi, A
Gion, M
Molina, R
Namer, M
Stieber, P
Sturgeon, C
Einarsson, R [1 ]
机构
[1] BEKI Diagnost AB, S-16866 Stockholm, Sweden
[2] Groene Hart Ziekenhuis, Dept Nucl Med, Gouda, Netherlands
[3] Hadassah Univ Hosp, IL-91120 Jerusalem, Israel
[4] Osped Treviglio, Bergamo, Italy
[5] San Giovanni Osped Civile, Venice, Italy
[6] Hosp Clin Prov, Barcelona, Spain
[7] Ctr Antoine Lacassagne, F-06054 Nice, France
[8] Univ Munich, Munich, Germany
[9] Univ Edinburgh, Edinburgh, Midlothian, Scotland
关键词
CA15-3; CEA; metastatic breast cancel; TPS;
D O I
10.1177/172460089801300103
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
TPS, CA 15-3 and CEA were determined in metastatic breast cancer patients during treatment. After six months of follow-up the patients were divided into four groups according to the UICC criteria for treatment response. Forty-six patients with a more favorable prognosis (complete remission, partial remission or stable disease) were followed for an extended period. In 30 of the 46 patients at least one marker had increased at the end of the six-month period by at least 25% (TPS in 54%, CA 15-3 in 20%, CEA in 20%). All these 30 patients subsequently developed progression. The prognostic sensitivity was 83%, 30% and 30%, respectively, for TPS, CA 15-3 and CEA. The combination of TPS and CA 15-3 showed a sensitivity of 96%. The median lead time was about 8 months for TPS and CA 15-3 but less than 50% of the patients showed a lead time for CA 15-3 as compared to TPS. We conclude that TPS and CA 15-3 determinations are helpful for the prediction of progression during the follow-up of breast cancer patients.
引用
收藏
页码:10 / 15
页数:6
相关论文
共 23 条
[1]  
Bast RC, 1996, J CLIN ONCOL, V14, P2843
[2]  
Bjorklund B, 1996, TUMORDIAGN THER, V17, P67
[3]  
BJORKLUND B, 1993, UPDATING TUMOR MARKE, P651
[4]  
Blijlevens NMA, 1995, ANTICANCER RES, V15, P2711
[5]   FROM ADJUVANT TO NEOADJUVANT CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER - THE EXPERIENCE OF THE MILAN CANCER INSTITUTE - STEINER AWARD LECTURE 1992 [J].
BONADONNA, G .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (01) :1-4
[6]  
Coveney E. C., 1995, International Journal of Biological Markers, V10, P35
[7]   CA 15-3 AND CARCINOEMBRYONIC ANTIGEN IN THE CLINICAL-EVALUATION OF BREAST-CANCER [J].
DNISTRIAN, AM ;
SCHWARTZ, MK ;
GREENBERG, EJ ;
SMITH, CA ;
SCHWARTZ, DC .
CLINICA CHIMICA ACTA, 1991, 200 (2-3) :81-93
[8]  
GION M, 1992, BREAST, V1, P173
[9]   ASSESSMENT OF RESPONSE TO THERAPY IN ADVANCED BREAST-CANCER - PROJECT OF PROGRAM ON CLINICAL ONCOLOGY OF "INTERNATIONAL-UNION-AGAINST-CANCER, GENEVA, SWITZERLAND [J].
HAYWARD, JL ;
CARBONE, PP ;
HEUSON, JC ;
KUMAOKA, S ;
SEGALOFF, A ;
RUBENS, RD .
EUROPEAN JOURNAL OF CANCER, 1977, 13 (01) :89-94
[10]   BREAST-CANCER AND CLINICAL UTILITY OF CA-15-3 AND CEA [J].
JAGER, W ;
KRAMER, S ;
PALAPELAS, V ;
NORBERT, L .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1995, 55 :87-92